Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology

By sjmartinez • March 15, 2025

Antonarelli G, Pérez-García JM, Gion M, Rugo H, Schmid P, Bardia A, Hurvitz S, Harbeck N, Tolaney SM, Curigliano G, Llombart-Cussac A, Cortés J. Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology. Ann Oncol. 2025 Mar 12:S0923-7534(25)00111-5. doi: 10.1016/j.annonc.2025.03.005. Epub ahead of print. PMID: 40086733.

Tags: clinical trials, Hematology/Oncology, Medical Oncology, Publications, Regulatory Approval, Strategic Design

Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome)

Daniel CE, Bejjani A. Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome). Cureus. 2025 Feb 10;17(2):e78827.[...]

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz[...]

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, Wander SA, Bardia A, Ko N, Moy B, Ellisen LW, Isakoff SJ. Dynamic[...]